| References: |
AT-7519 is an orally bioavailable small molecule CDK inhibitor with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are serine/theronine kinases involved in regulation of the cell cycle and may be overexpressed in some types of cancer cells. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
For the detailed information about the solubility of AT7519 HCL in water, the solubility of AT7519 HCL in DMSO, the solubility of AT7519 HCL in PBS buffer, the animal experiment（test） of AT7519 HCL,the in vivo,in vitro and clinical trial test of AT7519 HCL,the cell experiment（test） of AT7519 HCL,the IC50, EC50 and Affinity of AT7519 HCL, please contact DC Chemicals. |
